

## AMRYT AND SWIXX SIGN CEE DISTRIBUTION DEAL ON MYALEPTA

### SWIXX ANNOUNCEMENT NO. 31

June 3<sup>rd</sup>, 2020

**Baar, Switzerland** – Swixx BioPharma AG of Baar, Switzerland announced today the signing of a distribution agreement with Amryt Pharma Plc (“Amryt”) through its wholly owned subsidiary Aegerion Pharmaceuticals Limited. Under the agreement, Amryt has appointed Swixx as exclusive distributor of Myalepta® (metreleptin) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia. In addition, Swixx will distribute Myalepta® for Amryt in the West Balkan countries of Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia. Myalepta® has been approved by the EMA as a treatment, in conjunction with diet, to treat the complications of leptin deficiency in patients with generalized and partial lipodystrophy.

“It’s both exciting and a privilege for me to announce that Amryt has selected Swixx to assist to bring this new therapy to both CEE patients and CEE healthcare providers” commented Swixx Rare Disease Business Unit Head and Chief Commercial Officer (COO), Dr. Dezso Martha. Metreleptin is an important and breakthrough therapy for treating lipodystrophy and is eagerly awaited by patients across CEE. There is a definite unmet need for new therapies to treat the complications of leptin deficiency in patients with congenital or acquired generalised lipodystrophy and in a subset of patients with partial lipodystrophy.

This deal represents a rare disease milestone for Swixx” enthused Swixx’s CEO, Jean-Michel Lespinasse. “We embarked on building a rare disease business unit at Swixx just a year ago; inking this deal with Amryt both diversifies our company’s portfolio and validates Swixx as a strategic partner in rare and ultra-rare diseases in CEE. We thank our new colleagues at Amryt for affording Swixx this opportunity and we keenly anticipate working with lipodystrophy patients across the sixteen countries where Amryt has entrusted Swixx to distribute Myalepta.

### **About Swixx BioPharma AG**

Swixx operates fully owned subsidiaries across Central and Eastern Europe, offering coverage from Moscow to Prague and from Tallinn to Sofia. With 500 employees and sales exceeding 200M Euros in 2020, Swixx is now the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-hematology, specialty and self-medication talent under one roof. For more information about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com)

### **About Amryt**

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

For more information about Amryt, please visit: [www.amrytpharma.com](http://www.amrytpharma.com)

**Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.**

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

**Note on Unsubscribing from Swixx Announcement Mailing List:** *In accordance with the GDPR (General Data Protection Regulation) provisos of the EU, should you wish to unsubscribe / opt out of our mailing list, please send to [Maja.Boskovic@swixxbiopharma.com](mailto:Maja.Boskovic@swixxbiopharma.com) a one-line message „Please unsubscribe me.“*